Liana Moussatos
Stock Analyst at Wedbush
(2.98)
# 1,378
Out of 4,905 analysts
63
Total ratings
62.07%
Success rate
28.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liana Moussatos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLSD Clearside Biomedical | Maintains: Outperform | $5 → $4 | $0.41 | +878.00% | 4 | Mar 13, 2024 | |
| VRNA Verona Pharma | Reiterates: Outperform | $33 | $104.90 | -68.54% | 6 | Mar 1, 2024 | |
| UTHR United Therapeutics | Reiterates: Outperform | $308 | $292.01 | +5.48% | 10 | Feb 22, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $75 | $129.46 | -42.07% | 4 | May 23, 2023 | |
| LQDA Liquidia | Downgrades: Underperform | $4 → $3 | $14.54 | -79.37% | 5 | Sep 1, 2022 | |
| ASND Ascendis Pharma | Maintains: Outperform | $128 → $117 | $169.90 | -31.14% | 6 | Mar 3, 2022 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $97 → $94 | $21.59 | +335.49% | 9 | Feb 28, 2022 | |
| XOMA XOMA Royalty | Downgrades: Neutral | $22 | $25.67 | -14.30% | 5 | Sep 7, 2021 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Neutral | $2 → $8 | $1.23 | +550.41% | 3 | Jan 29, 2021 | |
| IMUX Immunic | Initiates: Outperform | $59 | $0.96 | +6,020.33% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $164 | $57.29 | +186.26% | 6 | Mar 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $36 | $4.20 | +757.14% | 4 | Feb 10, 2020 |
Clearside Biomedical
Mar 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $0.41
Upside: +878.00%
Verona Pharma
Mar 1, 2024
Reiterates: Outperform
Price Target: $33
Current: $104.90
Upside: -68.54%
United Therapeutics
Feb 22, 2024
Reiterates: Outperform
Price Target: $308
Current: $292.01
Upside: +5.48%
Blueprint Medicines
May 23, 2023
Reiterates: Outperform
Price Target: $75
Current: $129.46
Upside: -42.07%
Liquidia
Sep 1, 2022
Downgrades: Underperform
Price Target: $4 → $3
Current: $14.54
Upside: -79.37%
Ascendis Pharma
Mar 3, 2022
Maintains: Outperform
Price Target: $128 → $117
Current: $169.90
Upside: -31.14%
Pacira BioSciences
Feb 28, 2022
Maintains: Outperform
Price Target: $97 → $94
Current: $21.59
Upside: +335.49%
XOMA Royalty
Sep 7, 2021
Downgrades: Neutral
Price Target: $22
Current: $25.67
Upside: -14.30%
Lexicon Pharmaceuticals
Jan 29, 2021
Downgrades: Neutral
Price Target: $2 → $8
Current: $1.23
Upside: +550.41%
Immunic
Jun 5, 2020
Initiates: Outperform
Price Target: $59
Current: $0.96
Upside: +6,020.33%
Mar 2, 2020
Maintains: Outperform
Price Target: $175 → $164
Current: $57.29
Upside: +186.26%
Feb 10, 2020
Maintains: Outperform
Price Target: $35 → $36
Current: $4.20
Upside: +757.14%